This would mean faster profits since not having to pay for clinical trials.
This patent fail may be a blessing in disguise. I too think that whatever money this was costing can now be shifted to our 'main staple', with potential to RAPIDLY move up sales and boost the quarterly report. Onward and upward!!!!